C
Cellarity
Biotech & Life Sciences · Cambridge, United States · Founded 2017
Developing medicines through an understanding of cell behaviors MoreLess
Cellarity is a groundbreaking startup that is revolutionizing the process of drug creation. The company operates in the pharmaceutical industry, specifically in the area of drug discovery and development. They serve clients in the healthcare sector, including hospitals, clinics, and other medical institutions.
Cellarity's business model is centered around a novel approach to drug discovery. Unlike traditional methods that focus on single molecular targets, Cellarity targets the entire cell, which they believe is a more effective way to treat diseases. This approach is based on a deep understanding of disease biology and leverages advanced technologies like genomics, systems biology, data science, and artificial intelligence (AI).
The company's platform provides insights into cellular dysfunction, revealing new biology that can be used to treat a wide range of diseases. This includes diseases that have been overlooked or are too complex to resolve with traditional methods. With ongoing programs in hematology, immuno-oncology, and metabolism, Cellarity is at the forefront of creating a new generation of medicines.
Cellarity makes money by developing and selling these innovative drugs. Their interdisciplinary team of experts works together to create these new therapies, which are then sold to healthcare providers. The company's unique approach to drug discovery could potentially lead to more effective treatments for a variety of diseases, making it a promising player in the pharmaceutical industry.
Keywords: Drug Creation, Disease Biology, Cellular Dysfunction, Drug Discovery, Genomic Technologies, Systems Biology, Data Science, Artificial Intelligence, Hematology, Immuno-Oncology.
Company overview
Cellarity company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Employees
- 76
- Open positions
- None listed
- Dealroom signal
- 64.8
Valuation & funding
Cellarity funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2022 | $121M | $484M | BlackRock · Kyowa Kirin · The Baupost Group · Pictet | ↗ |
| SERIES BOther financing | Feb 2021 | $123M | $492M | BlackRock · Flagship Pioneering · The Baupost Group · Pictet | — |
| EARLY VCOther financing | Dec 2019 | $50M | $200M | Flagship Pioneering | — |
Growth signals
Cellarity website traffic
Latest recorded traffic for Cellarity is 5.8K monthly website visits, up 48.7% over the last three months. Cellarity's team declined 13.6% over the past year.
Hiring
Open positions at Cellarity
Current openings linked to this company in Dealroom.
Comparisons
Cellarity compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Cellarity's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Cellarity has talent and traffic
team presence
In the news
Latest news about Cellarity
Recent press, funding announcements, and product moves mentioning Cellarity — open to read from the original sources.
Market sentiment
What the market is saying about Cellarity
An AI-synthesized read of the highest-engagement posts about Cellarity on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellarity’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.













